Author Search

⇨ FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 11:58:33 ON 30 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Sep 2008 VOL 149 ISS 14
FILE LAST UPDATED: 29 Sep 2008 (20080929/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

⇨ D STAT QUE L39
L18 STR



Structure attributes must be viewed using STN Express query preparation.
L21 242 SEA FILE=REGISTRY SSS FUL L18
L33 STR



Structure attributes must be viewed using STN Express query preparation.

L35 141 SEA FILE=REGISTRY SUB=L21 SSS FUL L33
L36 62 SEA FILE=HCAPLUS ABB=ON PLU=ON L35
L37 52 SEA FILE=HCAPLUS ABB=ON PLU=ON L36 AND (PRY<=2002 OR AY<=2002 OR PY<=2002)
L38 20 SEA FILE=HCAPLUS ABB=ON PLU=ON MULLALLY J?/AU
L39 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L38 AND L37

⇨ D IBIB ED ABS HITSTR L39 1

L39 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:80455 HCAPLUS Full-text
DOCUMENT NUMBER: 140:139470
TITLE: α,β-unsaturated ketone as inhibitors of ubiquitin isopeptidases that induce p53-independent cell death and their therapeutic uses
INVENTOR(S): Mullally, James E.; Moos, Philip; Fitzpatrick, Frank A.
PATENT ASSIGNEE(S): University of Utah Research Foundation, USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009023	A2	20040129	WO 2003-US22576	20030718 ←
WO 2004009023	A3	20040617		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492523	A1	20040129	CA 2003-2492523	20030718 ←
AU 2003249320	A1	20040209	AU 2003-249320	20030718 ←
EP 1542682	A2	20050622	EP 2003-765765	20030718 ←
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

US 20060106099 A1 20060518 US 2005-521570 20051107 ←
PRIORITY APPLN. INFO.: US 2002-396584P P 20020718 ←
WO 2003-US22576 W 20030718

ED Entered STN: 01 Feb 2004

AB A novel class of inhibitors of ubiquitin isopeptidases is disclosed that cause tumor cell death via mol. Mechanisms independent of p53. Specifically, compds. Containing an α,β-unsatd. Ketone with a sterically accessible electrophilic β-carbon and related compds. Are identified herein. The α-carbon of at least one α,β-unsatd. Ketone moiety bears an electron withdrawing substituent which is selected from the group consisting of fluorine, chlorine, bromine, iodine, nitro, nitrilo and carboxy. The said carboxy group is an acid, ester of amide group. The said α,β-unsatd. Ketone comprises a conjugated cyclopentene moiety. Pharmaceutical compns. Comprising the inhibitor compds. And methods of using the compds. For treating a variety of disease , such as tumor, inflammation, autoimmune disease, restenosis and dry eye, are disclosed.

IT 96055-64-0 96055-65-1 96055-66-2
96055-68-4 160791-07-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α,β-unsatd. Ketone as inhibitors of ubiquitin isopeptidases that induce p53-independent cell death and their therapeutic uses)

RN 96055-64-0 HCAPLUS
CN Prosta-10,14-dien-1-oic acid, 5,6,7-tris(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7R,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-65-1 HCAPLUS
CN Prosta-7,10,14,17-tetraen-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-_ydroxyl-9-oxo-, methyl ester, (5S,6S,7E,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-66-2 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-68-4 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 160791-07-1 HCAPLUS
CN Prosta-10,14-dien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



Structure Search

```
=> D STAT QUE L37
L18             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L21         242 SEA FILE=REGISTRY SSS FUL L18
L33             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L35         141 SEA FILE=REGISTRY SUB=L21 SSS FUL L33
L36          62 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L35
L37          52 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L36 AND (PRY<=2002 OR
                AY<=2002 OR PY<=2002)


=> S L37 NOT L39
L43         51 L37 NOT L39

=> D IBIB ED ABS HITSTR L43 1-51

L43  ANSWER 1 OF 51  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2001:916991  HCAPLUS  Full-text
DOCUMENT NUMBER:          136:232135
TITLE:                    Prostanoids: LXXX. Analogs of "marine" prostanoids.
                          (±)-11-chlorochlorovulone II
AUTHOR(S):                Akhmetvaleev, R. R.; Baibulatova, G. M.; Nuriev, I.
                          F.; Shitikova, O. V.; Miftakhov, M. S.
CORPORATE SOURCE:         Institute of Organic Chemistry, Ufa Scientific Center,
                          Russian Academy of Sciences, Ufa, 450054, Russia
SOURCE:                   Russian Journal of Organic Chemistry (Translation of
                          Zhurnal Organicheskoi Khimii) (2001), 37(8),
                          1083-1087
```

CODEN: RJOCEQ; ISSN: 1070-4280
PUBLISHER: MAIK Nauka/Interperiodica Publishing
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:232135
ED Entered STN: 20 Dec 2001
GI



I



II

AB Analog of chlorovulone II (I) containing an extra chlorine atom at C11 was synthesized starting with 1,4-dioxa-6,7-dichlorospiro[4,4]non-6-ene (II).

IT 100295-80-5P, Chlorovulone II
RL: SPN (Synthetic preparation); PREP (Preparation)
(analog; preparation of chlorovulone II analog from 1,4-dioxa-6,7-dichlorospiro[4,4]non-6-ene)

RN 100295-80-5 HCAPLUS

CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 2 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:785496 HCAPLUS Full-text
DOCUMENT NUMBER: 136:67131
TITLE: New halogenated marine prostanoids with cytotoxic activity from the Okinawan soft coral Clavularia viridis
AUTHOR(S): Watanabe, Kinzo; Sekine, Miyuki; Takahashi, Haruko; Iguchi, Kazuo
CORPORATE SOURCE: School of Life Science, Tokyo University of Pharmacy and Life Science, Hachioji, Tokyo, 192-0392, Japan
SOURCE: Journal of Natural Products (2001), 64(11), 1421-1425
CODEN: JNPRDF; ISSN: 0163-3864
PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 30 Oct 2001
GI



AB Five new halogenated prostanoids (I-V) were isolated from the Okinawan soft coral Clavularia viridis. The gross structure of I was elucidated mainly on the basis of NMR spectral data. The relative and absolute configurations were determined by anal. of NOESY and CD data, chemical conversion, and the modified Mosher's method. The structures of II-IV and V were deduced by comparison of their spectral data with those of I. Compound I demonstrated cytotoxic activity.

IT 160791-09-3, Punaglandin 8
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(halogenated marine prostanoids with cytotoxic activity from Okinawan soft coral Clavularia viridis)

RN 160791-09-3 HCAPLUS

CN Prosta-5,10,14-trien-1-oic acid, 7-(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5Z,7S,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 383414-92-4P
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(halogenated marine prostanoids with cytotoxic activity from Okinawan soft coral Clavularia viridis)

RN 383414-92-4 HCAPLUS

CN Prosta-5,10,14-trien-1-oic acid, 7-(acetyloxy)-12-hydroxy-10-iodo-9-oxo-, methyl ester, (5Z,7S,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



IT 383414-93-5P 383414-94-6P 383414-95-7P
383414-96-8P
RL: NPO (Natural product occurrence); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(halogenated marine prostanoids with cytotoxic activity from Okinawan soft coral Clavularia viridis)

RN 383414-93-5 HCAPLUS
CN Prosta-5,10,14-trien-1-oic acid, 7-(acetyloxy)-12-hydroxy-10-iodo-9-oxo-, methyl ester, (5E,7S,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 383414-94-6 HCAPLUS
CN Prosta-5,10,14-trien-1-oic acid, 7-(acetyloxy)-10-bromo-12-hydroxy-9-oxo-, methyl ester, (5Z,7S,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 383414-95-7 HCAPLUS
CN Prosta-5,10,14-trien-1-oic acid, 7-(acetyloxy)-10-bromo-12-hydroxy-9-oxo-, methyl ester, (5E,7S,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 383414-96-8 HCAPLUS
CN Prosta-5,10,14-trien-1-oic acid, 7-(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7S,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



IT 105343-03-1P, Iodovulone I 383414-97-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation from 7-acetoxy-7,8-dihydroiodovulone I)
RN 105343-03-1 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 12-hydroxy-10-iodo-9-oxo-, methyl ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383414-97-9 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 12-hydroxy-10-iodo-9-oxo-, methyl ester, (5Z,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 3 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:537512 HCAPLUS Full-text
DOCUMENT NUMBER: 129:316062
ORIGINAL REFERENCE NO.: 129:64499a,64502a
TITLE: Application of a novel carbonyl ene reaction: total syntheses of phyllanthocin and chlorovulone II
AUTHOR(S): Zhu, Shuren
CORPORATE SOURCE: Rice Univ., Houston, TX, USA
SOURCE: (1998) 163 pp. Avail.: UMI, Order No. DA9827467
From: Diss. Abstr. Int., B 1998, 59(3), 1121
DOCUMENT TYPE: Dissertation
LANGUAGE: English
ED Entered STN: 25 Aug 1998
AB Unavailable
IT 100295-80-5P, Chlorovulone II
RL: SPN (Synthetic preparation); PREP (Preparation)
(total syntheses of phyllanthocin and chlorovulone II via carbonyl ene reaction)
RN 100295-80-5 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 4 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:355711 HCAPLUS Full-text
DOCUMENT NUMBER: 129:122470
ORIGINAL REFERENCE NO.: 129:25097a,25100a
TITLE: A carbohydrate approach to 4-hydroxy-2-cyclopentenone

moiety of antitumor prostanoid punaglandin IV via alkylation of ester uronate

AUTHOR(S): Kuhn, Cyrille; Florent, Jean-Claude

CORPORATE SOURCE: Unite Mixte Recherche, Inst. Curie-CNRS, Paris, 75248, Fr.

SOURCE: Tetrahedron Letters (1998), 39(24), 4247-4250
CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 129:122470

ED Entered STN: 12 Jun 1998

GI



AB An efficient and stereoselective synthesis of chiral precursor I of 2-chloro-4-hydroxy-4-alkyl-2-cyclopentenone, e.g. II, has been realized by alkylation of a sugar Me uronate derived from 1,2-O-isopropylidene-α- D-glucose with an acetonyl equivalent, and subsequent intramol. Wittig reaction.

IT 96055-66-2P, Punaglandin IV
RL: PNU (Preparation, unclassified); PREP (Preparation)
(carbohydrate approach to the hydroxycyclopentenone moiety of punaglandin IV via alkylation of an ester uronate)

RN 96055-66-2 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 5 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:355693 HCAPLUS Full-text

DOCUMENT NUMBER: 129:122469
ORIGINAL REFERENCE NO.: 129:25097a,25100a
TITLE: Cross-conjugated cyclopentenone prostaglandins synthesis of Δ7-10-chloro-15-deoxy PGA1 ethyl ester
AUTHOR(S): Tius, Marcus A.; Busch-Petersen, Jakob; Yamashita, Mason
CORPORATE SOURCE: Dep. Chem., Univ. Hawaii, Honolulu, HI, 96822, USA
SOURCE: Tetrahedron Letters (1998), 39(24), 4219-4222
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:122469
ED Entered STN: 12 Jun 1998
GI



I



II

AB The cationic cyclopentannelation reaction, e.g. cyclization of MeOCH2OCH:C:CH(CH2)4C.tplbond.COEt to cyclopentenone I, provides an unconventional but highly efficient strategy for the synthesis of unsatd. prostanoids and their analogs, e.g. II [R = OH, OAc, OC(:S)NMe2, Cl]. II were evaluated against KB and LoVo cell lines [IC50 = 80 μM (KB), 101 μM (LoVo) {I; R = OH}; IC50 = 53 μM (KB), 49 μM (LoVo) {I; R = OAc}; IC50 = 0.13 μM (KB), 1.3 μM (LoVo) {I; R = OC(:S)NMe2}; IC50 = 7 μM (KB), 57 μM (LoVo) {I; R = Cl}].

IT 96055-66-2DP, Punaglandin 4, analog
RL: PNU (Preparation, unclassified); PREP (Preparation)
(synthesis of cross-conjugated cyclopentenone prostaglandins via a cationic cyclopentannelation reaction)

RN 96055-66-2 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 6 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:218250 HCAPLUS Full-text
DOCUMENT NUMBER: 128:270449
ORIGINAL REFERENCE NO.: 128:53537a,53540a
TITLE: A novel chloroenone synthesis with dichloromethylenedimethylammonium chloride: synthesis of 12-deoxychlorovulone analogs
AUTHOR(S): Chen, Yung-Fa
CORPORATE SOURCE: Product Development Dep., Refining and Manufacturing Res. Cent., Chinese Petroleum Corp., Chiayi, Taiwan
SOURCE: Taiwan Kexue (1997), 50(1), 92-120
CODEN: TKHSAU; ISSN: 0015-7791
PUBLISHER: Formosan Association for Advancement of Science
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 128:270449
ED Entered STN: 18 Apr 1998
GI



I



II

AB A variety of 12-deoxychlorovulone II analogs such as I [R = (CH2)5CO2Me, R1 = H, Me, CHMe2, (CH2)3Me, (CH2)7Me; R = (E)-CH:CH(CH2)3CO2Me, C.tplbond.C(CH2)3CO2Me, R1 = (CH2)7Me] were prepared by acid catalyzed deprotection of the corresponding acetonides II followed by nucleophilic chloride substitution catalyzed by Viehe's salt, C12C:N+Me2Cl-, in the presence of Et3N.

IT 100295-80-5P, Chlorovulone II, 12-deoxy analogs
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of 12-deoxychlorovulone II analogs via chloride nucleophilic substitution reaction catalyzed by Viehe's salt)

RN 100295-80-5 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 7 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:143663 HCAPLUS Full-text
DOCUMENT NUMBER: 128:127831
ORIGINAL REFERENCE NO.: 128:25107a,25110a
TITLE: Practical Synthesis of (±)-Chlorovulone II
AUTHOR(S): Ciufolini, Marco A.; Zhu, Shuren
CORPORATE SOURCE: Department of Chemistry, Rice University, Houston, TX, 77005-1892, USA
SOURCE: Journal of Organic Chemistry (1998), 63(5), 1668-1675
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 128:127831
ED Entered STN: 10 Mar 1998
GI



I

AB A total synthesis of (±)-chlorovulone II (I) that is 10 steps shorter than the best alternative currently available (nine vs 19 steps) is described. The key event of the synthesis is an aldol addition of the enolate of Et acetate into 4-cyclopentene-1,3-dione, a substance that has received little attention as an educt for prostanoid synthesis and for which little is known about carbonyl 1,2-addition with enolates. In addition, the chemical and stereochem. details of a route to a key intermediate toward the title compound that involves a carbonyl-ene reaction and a radical addition to an aldehyde carbonyl is provided.

IT 201802-89-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(practical synthesis of chlorovulone II via an aldol addition to cyclopentenedione)

RN 201802-89-3 HCAPLUS

CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl

ester, (5E,7E,12ξ,14Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 8 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:760118 HCAPLUS Full-text
DOCUMENT NUMBER: 128:88377
ORIGINAL REFERENCE NO.: 128:17265a,17268a
TITLE: A remarkable ene-like reaction: development and synthetic applications
AUTHOR(S): Ciufolini, Marco A.; Deaton, Melissa V.; Zhu, Shuren; Chen, Mingying
CORPORATE SOURCE: Department of Chemistry, Rice University, Houston, TX, 77005-1892, USA
SOURCE: Tetrahedron (1997), 53(48), 16299-16312
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 128:88377
ED Entered STN: 06 Dec 1997
AB A catalytic ene-like reaction of aldehydes with those vinyl ethers that display the oxygen functionality at the central carbon of an allylic system, e.g., 2-methoxypropene, was discussed in detail. The reaction was promoted by 0.05 equivalent of the 1:1 complex of Yb(fod)3 and acetic acid, and it formed the centerpiece of the synthesis of chlorovulone II, mitomycinoids and phyllanthocin.
IT 100295-80-5P, Chlorovulone II
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 100295-80-5 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 74 THERE ARE 74 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 9 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:228132 HCAPLUS Full-text
DOCUMENT NUMBER: 122:102045
ORIGINAL REFERENCE NO.: 122:19127a,19130a
TITLE: The punaglandins: 10-chloroprostanoids from the octocoral Telesto riisei
AUTHOR(S): Baker, Bill J.; Scheuer, Paul J.
CORPORATE SOURCE: Dep. Chem., Univ. Hawaii at Manoa, Honolulu, HI, 96822, USA
SOURCE: Journal of Natural Products (1994), 57(10), 1346-53
CODEN: JNPRDF; ISSN: 0163-3864
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 06 Dec 1994
GI



I

AB Telesto riisei, an octocoral from Hawaii, produces nineteen highly functionalized prostanoids, the punaglandins, which are characterized by various oxygenation at C-5, -6, -7, and -12, and a 10-chloro-9- cyclopentenone moiety. The absolute stereochem. of the 10-chloroprostanoids, including Punaglandin 5 (I), is epimeric to that of the Pacific marine prostanoids without halogen. The punaglandins have shown anti-inflammatory and antitumor activity. A synthetic 10-thiomethyl derivative enhances in vivo mineralization in human osteoblasts.

IT 96055-63-9, Punaglandin 1 96055-64-0, Punaglandin 2 96055-65-1, Punaglandin 3 96055-66-2, Punaglandin 4 96055-67-3 96055-68-4 160791-06-0, Punaglandin 5 160791-07-1, Punaglandin 6 160791-08-2, Punaglandin 7 160791-09-3, Punaglandin 8
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(punaglandin isolation and structural characterization and antineoplastic activity from Hawaiian octocoral)

RN 96055-63-9 HCAPLUS
CN Prosta-10,14,17-trien-1-oic acid, 5,6,7-tris(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7R,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-64-0 HCAPLUS
CN Prosta-10,14-dien-1-oic acid, 5,6,7-tris(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7R,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-65-1 HCAPLUS
CN Prosta-7,10,14,17-tetraen-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-66-2 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-67-3 HCAPLUS
CN Prosta-7,10,14,17-tetraen-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-68-4 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 160791-06-0 HCAPLUS
CN Prosta-10,14,17-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 160791-07-1 HCAPLUS
CN Prosta-10,14-dien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 160791-08-2 HCAPLUS
CN Prosta-5,10,14,17-tetraen-1-oic acid, 7-(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5Z,7S,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 160791-09-3 HCAPLUS
CN Prosta-5,10,14-trien-1-oic acid, 7-(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5Z,7S,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 10 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:533752 HCAPLUS Full-text
DOCUMENT NUMBER: 121:133752
ORIGINAL REFERENCE NO.: 121:24173a,24176a
TITLE: Natural products synthesis by retro-Diels-Alder reaction. VIII. A concise stereospecific formal synthesis of tetrahydrochlorovulone

AUTHOR(S): Liu, Zhiyu; Yang, Jiying; Zhang, Jianjun; Tao, Xueliang
CORPORATE SOURCE: Shanghai Inst. Org. Chem., Chin. Acad. Sci., Shanghai, 200032, Peop. Rep. China
SOURCE: Chinese Chemical Letters (1993), 4(11), 947-8
CODEN: CCLEE7; ISSN: 1001-8417
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 121:133752
ED Entered STN: 17 Sep 1994
GI



AB A potent antineoplastic tetrahydrochlorovulone I was synthesized by retro-Diels Alder reaction of tricyclic ketone II to give cyclopentenone III as a key step.
IT 102355-12-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereospecific preparation of, via retro Diels-Alder)
RN 102355-12-4 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (7E,12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L43 ANSWER 11 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:533585 HCAPLUS Full-text
DOCUMENT NUMBER: 121:133585
ORIGINAL REFERENCE NO.: 121:24141a,24144a
TITLE: Preparation of 4-hydroxy-2-cyclopentenone derivative and carcinostatic and osteogenesis promoter containing the same

INVENTOR(S): Furuya, Minoru; Sugiura, Satoshi; Hazato, Atsuo
PATENT ASSIGNEE(S): Teijin Ltd., Japan
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9405619	A1	19940317	WO 1993-JP1266	19930907 <--
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9349829	A	19940329	AU 1993-49829	19930907 <--
AU 678389	B2	19970529		
EP 659728	A1	19950628	EP 1993-919623	19930907 <--
R: CH, DE, FR, GB, IT, LI, NL, SE				
CA 2144313	C	19990330	CA 1993-2144313	19930907 <--
US 5675031	A	19971007	US 1995-397176	19950308 <--
PRIORITY APPLN. INFO.:			JP 1992-241998 A	19920910 <--
			WO 1993-JP1266 W	19930907 <--

OTHER SOURCE(S): MARPAT 121:133585
ED Entered STN: 17 Sep 1994
GI



AB An optically active compound represented by general formula [I; Y = H, halo; A = OH, C2-7 acyloxy, C2-5 alkoxycarbonyloxy, or C1-7 sulfonyloxy and B = H, or alternatively A and B are combined together to represent a bond; R2 = C4-10 alicyclic hydrocarbon, C6-10 aromatic hydrocarbon or C1-9 heterocyclic hydrocarbon group each of which may be substituted; R3 = H or C1-10 aliphatic hydrocarbon, C4-10 alicyclic hydrocarbon or C6-10 aromatic hydrocarbon group each of which may be substituted; R4 = H, C1-4 alkyl, C2-7 acyl, C2-5 alkoxycarbonyl, tri(C1-7 hydrocarbyl)silyl or a group which forms an acetal bond together with the oxygen atom to which R4 is bonded; R5 = H or C1-10 aliphatic hydrocarbon or C4-10 alicyclic hydrocarbon group each of which may be substituted] or a mixture thereof, useful as anticancer agents and for the treatment of osteoporosis and osteomalacia, are prepared A carcinostatic and osteogenesis promoter each containing the hydroxycyclopentenone derivative I as the active ingredient is claimed. Thus, (dL)-4-hydroxy-2-cyclopentenone derivative (II; R = H) was treated with LiN(CHMe2)2 in THF at -78° and condensed with cyclohexanecarbaldehyde to give 67% II (R = Q) which was

mesylated by MeSO2Cl in pyridine followed by elimination reaction using DBU in CH2Cl2 to give (cyclohexylmethylene)cyclopentenone derivative (III; R = cyclohexyl, R1 = Me3Si, X = Cl) and its isomer. Benzylidenecyclopentenone III (R = 4-methoxycarbonylphenyl, R1 = H, X = Cl) showed IC50 of 0.004 μg/mL for inhibiting L1210 leukemia cells.

IT 157121-52-3P 157121-53-4P 157121-54-5P
157121-55-6P 157121-56-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as anticancer agent and osteogenesis promoter)

RN 157121-52-3 HCAPLUS
CN Benzoic acid, 4-[[4-chloro-2-hydroxy-5-oxo-2-(4-phenoxybutyl)-3-cyclopenten-1-ylidene]methyl]-, methyl ester (CA INDEX NAME)



RN 157121-53-4 HCAPLUS
CN 2-Cyclopenten-1-one, 2-chloro-5-[[4-(dimethylamino)phenyl]methylene]-4-hydroxy-4-(4-phenoxybutyl)- (CA INDEX NAME)



RN 157121-54-5 HCAPLUS
CN Benzoic acid, 4-[[4-fluoro-2-hydroxy-5-oxo-2-(4-phenoxybutyl)-3-cyclopenten-1-ylidene]methyl]-, methyl ester (CA INDEX NAME)



RN 157121-55-6 HCAPLUS
CN 2-Cyclopenten-1-one, 2-chloro-4-(3,7-dimethyl-6-octen-1-yl)-4-hydroxy-5-(4-pyridinylmethylene)- (CA INDEX NAME)



RN 157121-56-7 HCAPLUS
CN 2-Cyclopenten-1-one, 2-chloro-4-(6-cyclohexylhexyl)-4-hydroxy-5-[[4-[3-hydroxy-2-(hydroxymethyl)propyl]phenyl]methylene]- (CA INDEX NAME)



L43 ANSWER 12 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:76680 HCAPLUS Full-text
DOCUMENT NUMBER: 112:76680
ORIGINAL REFERENCE NO.: 112:13095a,13098a
TITLE: Synthesis of 10-halogenated clavulone derivatives
AUTHOR(S): Iguchi, Kazuo; Kaneta, Soichiro; Tsune, Chieko; Yamada, Yasuji
CORPORATE SOURCE: Tokyo Coll. Pharm., Tokyo, 192-03, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1989), 37(5), 1173-5
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 112:76680
ED Entered STN: 03 Mar 1990
GI



II

AB Epoxidn. of clavulone II with Me3COOH gave the (10R,11S)-epoxide (I) stereoselectively. Haloclavulones II (R = Cl, Br, iodo) were obtained from I and LiR and II (R = F) with KF-HF.

IT 111695-42-2P 111695-43-3P 125159-68-4P
125159-69-5P 125159-70-8P 125159-71-9P
125159-72-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 111695-42-2 HCAPLUS

CN Prosta-5,7,10,14-tetraen-1-oic acid, 4-(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (4R,5E,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 111695-43-3 HCAPLUS

CN Prosta-5,7,10,14-tetraen-1-oic acid, 4-(acetyloxy)-10-fluoro-12-hydroxy-9-oxo-, methyl ester, (4R,5E,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 125159-68-4 HCAPLUS

CN Prosta-5,7,10,14-tetraen-1-oic acid, 4-(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (4R,5E,7Z,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 125159-69-5 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 4-(acetyloxy)-10-bromo-12-hydroxy-9-oxo-, methyl ester, (4R,5E,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 125159-70-8 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 4-(acetyloxy)-10-bromo-12-hydroxy-9-oxo-, methyl ester, (4R,5E,7Z,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 125159-71-9 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 4-(acetyloxy)-12-hydroxy-10-iodo-9-oxo-, methyl ester, (4R,5E,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 125159-72-0 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 4-(acetyloxy)-12-hydroxy-10-iodo-9-oxo-, methyl ester, (4R,5E,7Z,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 13 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:632451 HCAPLUS Full-text
DOCUMENT NUMBER: 111:232451
ORIGINAL REFERENCE NO.: 111:38605a,38608a
TITLE: Preparation of punaglandin derivatives
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62234060	A	19871014	JP 1986-76213	19860401 <--
PRIORITY APPLN. INFO.:			GB 1985-8422 A	19850401 <--

OTHER SOURCE(S): CASREACT 111:232451
ED Entered STN: 23 Dec 1989
GI



I



II



III

AB The title compds. I (R1-R3 = lower alkyl), useful as potential anticancer agents, are prepared from II (R4 = hydroxy-protecting group). Dehydration of Me 5,6-(isopropylidenedioxy)-7-hydroxy-7-[(2R)-2-methoxymethoxy-2-octyl- 4-chloro-5-oxo-3-cyclopenten-1-yl]heptanoate (preparation given), followed by dealkylation, acetylation, and deprotection, gave III.

IT 102354-92-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as potential anticancer agent)

RN 102354-92-7 HCAPLUS

CN Prosta-7,10-dien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7E,12α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 14 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:553507 HCAPLUS Full-text
DOCUMENT NUMBER: 111:153507
ORIGINAL REFERENCE NO.: 111:25581a,25584a
TITLE: Alkynylcyclopentenol derivatives as punaglandin intermediates and their preparation
INVENTOR(S): Mori, Kenji; Takeuchi, Tei; Yuya, Masakazu; Takeda, Shigeo
PATENT ASSIGNEE(S): Fuji Chemicals Industrial Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01026529	A	19890127	JP 1987-183042	19870722 <--
PRIORITY APPLN. INFO.:			JP 1987-183042	19870722 <--

OTHER SOURCE(S): MARPAT 111:153507
ED Entered STN: 28 Oct 1989
GI



I

AB The title compds. I (R1 = OH-protecting group; X = halo; R2 = H; the asterisk indicates asym. C), useful as intermediates for antitumor and antiviral punaglandin, were prepared Treatment of HC.tplbond.CMe with BuLi, followed by reaction with (4R)-4-tert-butyldimethylsilyloxy-3-chloro-2- cyclopentenone, gave 84.5% (1R,4S)-1-(tert-butyldimethyl)silyloxy-2-chloro- 4-(2-propynyl)cyclopent-2-en-4-ol.

IT 96055-66-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(intermediates for, preparation of alkynylcyclopentenol derivs. as)

RN 96055-66-2 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 15 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:514961 HCAPLUS Full-text
DOCUMENT NUMBER: 111:114961
ORIGINAL REFERENCE NO.: 111:19271a,19274a
TITLE: Preparation of 1-halo-2,3,4-trioxybutanes as intermediates for anticancer punaglandin
INVENTOR(S): Mori, Kenji; Takeuchi, Tei; Yuya, Masakazu; Takeda, Shigeo

PATENT ASSIGNEE(S): Fuji Chemicals Industrial Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01026575	A	19890127	JP 1987-183043	19870722 <--
PRIORITY APPLN. INFO.:			JP 1987-183043	19870722 <--

OTHER SOURCE(S): MARPAT 111:114961
ED Entered STN: 01 Oct 1989
AB R1OCH2CHOR2CHOR3CH2X (I) (R1-R3 = OH-protecting group; OR2R3O = acetal; X = halo), useful as intermediates for anticancer punaglandin, were prepared Reaction of (4S,5S)-4-benzyloxymethyl-5-hydroxymethyl-2,2-dimethyl-1,3-dioxolane with MeSO2Cl, followed by treatment with NaI and addition reaction of the resulting product with CH2:CHCO2Me in the presence of Bu3SnCl and NaBH4 under a Hg lamp, gave (5S,6S)-5,6-isopropylidenedioxy-7- benzyloxyheptanoic acid Me ester.
IT 96055-66-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(intermediates for, halotrioxybutanes as)
RN 96055-66-2 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 16 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:434116 HCAPLUS Full-text
DOCUMENT NUMBER: 111:34116
ORIGINAL REFERENCE NO.: 111:5737a,5740a
TITLE: Cytotoxic action of prostaglandins on human retinoblastoma cell line, Y-79
AUTHOR(S): Nakamura, Masao; Koshihara, Yasuko; Mochizuki, Manabu; Masuda, Kanjiro
CORPORATE SOURCE: Dep. Ophthalmol., Asahi-Chuou Hosp., Chiba, 289-25, Japan
SOURCE: Atarashii Ganka (1989), 6(4), 569-75
CODEN: ATGAEX; ISSN: 0910-1810
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
ED Entered STN: 05 Aug 1989
GI



I

AB Cultured Y-79 cells produced no detectable PGD2, PGE2, PGF2α, thromboxane B2, or 6-oxo-PGF1α, suggesting the absence of an endogenous self-regulatory system of prostaglandins in Y-79 cell growth in vitro. Exogenously added PGE1, PGE2, and PGF2α had no effects on Y-79 cell growth in vitro at concns. of 1-20 μg/mL. However, PGA1, PGA2, PGD2, PGJ2, and especially 64E (I), inhibited cell growth. S.c. injection of 2-4 mg PGD2/kg/day suppressed and 4 mg I/kg/day strongly suppressed the in vivo growth of retinoblastoma in the nude mouse.

IT 114247-16-4
RL: PROC (Process)
(cytotoxic action of, on human retinoblastoma)

RN 114247-16-4 HCAPLUS

CN Prosta-5,7,10-trien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7E,12α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 17 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:107604 HCAPLUS Full-text

DOCUMENT NUMBER: 110:107604

ORIGINAL REFERENCE NO.: 110:17587a,17590a

TITLE: Structure requirements for antiproliferative and cytotoxic activities of marine coral prostanoids from the Japanese stolonifer Clavularia viridis against human myeloid leukemia cells in culture

AUTHOR(S): Honda, Atsushi; Mori, Yo; Iguchi, Kazuo; Yamada, Yasuji

CORPORATE SOURCE: Dep. Biochem., Tokyo Coll. Pharm., Hachioji, 192-03, Japan

SOURCE: Prostaglandins (1988), 36(5), 621-30
CODEN: PRGLBA; ISSN: 0090-6980

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 03 Apr 1989

AB The structure-antiproliferative and cytotoxic activity relationships of marine coral prostanoids from Japanese stolonifer C. viridis and related compds. were

examined in HL-60 cells in culture. The alkylidenecyclopentenone structure in these prostanoids was required for the antiproliferative and cytotoxic activities against HL-60 cells, but the epoxy prostanoids without cross-conjugated cyclopentenone system also had the activities. The presence of the OH group at the C-12 position in the prostanoids enhanced the activities, but the stereospecificity of the 12-OH group was not required for the activities. Introduction of halogen atom at the C-10 position of the prostanoids potentiated the activities (Cl > Br = I > H). Introduction of groups for blocking β-oxidation to the α-side chain of the prostanoids did not increase the activities. The presence of dienone (C5-6 and C7-8) in the structure potentiated the activities. The results provide the basis for designing a new class of antitumor agent from marine coral prostanoids.

IT 100295-81-6, Chlorovulone I 105343-03-1, Iodovulone I
105343-04-2, Bromovulone I 111695-42-2
RL: PRP (Properties)
(cytotoxicity of, to human myeloid leukemia cells, structure in relation to)

RN 100295-81-6 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105343-03-1 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 12-hydroxy-10-iodo-9-oxo-, methyl ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105343-04-2 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-bromo-12-hydroxy-9-oxo-, methyl ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 111695-42-2 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 4-(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (4R,5E,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 18 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:597063 HCAPLUS Full-text
DOCUMENT NUMBER: 109:197063
ORIGINAL REFERENCE NO.: 109:32509a,32512a
TITLE: Prolonged survival time of sarcoma 180-bearing mice treated with lipid microspheres-entrapped antitumor marine coral prostanoids
AUTHOR(S): Honda, Atsushi; Mori, Yo; Yamada, Yasuji; Nakaike, Shiro; Hayashi, Hidefumi; Otomo, Susumu
CORPORATE SOURCE: Dep. Biochem., Tokyo Coll. Pharm., Hachioji, 192-03, Japan
SOURCE: Research Communications in Chemical Pathology and Pharmacology (1988), 61(3), 413-16
CODEN: RCCCB8; ISSN: 0034-5164
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 25 Nov 1988
AB Antitumor marine coral prostanoids (clavulone II and chlorovulone I) were entrapped into lipid microspheres of 0.2 μm diameter to make lipo-drugs. Daily treatment with lipo-chlorovulone I (1.6 mg/kg/day, i.p.) and lipo-clavulone II (12.5 mg/kg/day, i.p.) on days 1 through 5 markedly prolonged the survival time (135 and 73% ILS, resp.) of mice inoculated with sarcoma 180 as compared with that of a corresponding dose of resp. free chlorovulone I and clavulone II. Thus, the lipid microspheres may be used as drug delivery carriers for antitumor coral prostanoids in vivo.
IT 100295-81-6, Chlorovulone I
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(marine coral, lipid microspheres containing, antitumor activity of)
RN 100295-81-6 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl

ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 19 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:549198 HCAPLUS Full-text
DOCUMENT NUMBER: 109:149198
ORIGINAL REFERENCE NO.: 109:24803a,24806a
TITLE: Preparation of fluorocyclopentenone derivatives as anticancer agents
INVENTOR(S): Hasato, Atsuo; Kurozumi, Seiji; Suzuki, Masaaki; Noyori, Ryoji
PATENT ASSIGNEE(S): Teijin Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63072672	A	19880402	JP 1986-217255	19860917 <--
PRIORITY APPLN. INFO.:			JP 1986-217255	19860917 <--

OTHER SOURCE(S): MARPAT 109:149198
ED Entered STN: 28 Oct 1988
GI



I II



III IV

AB The title compds. I [R1 = (substituted) C1-10 alkyl; R2 = (substituted) alkyl, alkenyl; R3 = H, tri(C1-7)hydrocarbylsilyl, group forming acetal bond with O of OH group; R4 = H; R5 = OH; R4R5 = bond], useful as anticancer agents (no

data), were prepared from cyclopentenone II [R6 = tri(C1-7)hydrocarbylsilyl, group forming acetal bond with O of OH group] and cyclopentenone III. Aldol condensation of II (R2 = octyl, R6 = Me3Si) with Me 7-oxoheptanoate, followed by dehydration and deprotection, gave title compds. (E)- and (Z)-IV.

IT 116752-44-4P 116752-45-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as anticancer agent)

RN 116752-44-4 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 10-fluoro-12-hydroxy-9-oxo-, methyl ester, (7E,12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 116752-45-5 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 10-fluoro-12-hydroxy-9-oxo-, methyl ester, (7Z,12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L43 ANSWER 20 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:528635 HCAPLUS Full-text
DOCUMENT NUMBER: 109:128635
ORIGINAL REFERENCE NO.: 109:21417a,21420a
TITLE: Preparative bioorganic chemistry. 9. Synthesis of punaglandin 4 by means of enzymatic resolution of the key chlorocyclopentene derivative
AUTHOR(S): Mori, Kenji; Takeuchi, Tadashi
CORPORATE SOURCE: Dep. Agric. Chem., Univ. Tokyo, Tokyo, 113, Japan
SOURCE: Tetrahedron (1988), 44(2), 333-42
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 109:128635
ED Entered STN: 14 Oct 1988

GI



I

AB Punaglandin (I) a chlorinated marine prostanoid, was synthesized from (+)-tartaric acid and (1S,4R)-(-)-4-tert-butyldimethylsilyloxy-3-chloro-2-cyclopenten-1-ol, which was prepared by asym. hydrolysis of the (±)-acetate with pig pancreatic lipase.

IT 96055-68-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 96055-68-4 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 96055-66-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of)

RN 96055-66-2 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 21 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:454569 HCAPLUS Full-text
DOCUMENT NUMBER: 109:54569
ORIGINAL REFERENCE NO.: 109:9191a,9194a
TITLE: Preparation of prostaglandins as antitumor agents
PATENT ASSIGNEE(S): Teijin Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 43 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
JP 62096438	A	19870502	JP 1986-108664		19860514	<--
JP 06043360	B	19940608				
US 4711895	A	19871208	US 1985-791156		19851022	<--
PRIORITY APPLN. INFO.:			US 1985-791156	A	19851022	<--
			JP 1984-220475	A	19841022	<--
			JP 1984-220476	A	19841022	<--
			JP 1985-28429	A	19850218	<--
			JP 1985-130845	A	19850618	<--

OTHER SOURCE(S): CASREACT 109:54569
ED Entered STN: 19 Aug 1988
GI



AB The title compds. I [X = H, halo; A = H and B = OH, or AB = bond; R1 = (substituted) C1-10 alkyl, alkenyl, alkynyl; R2 = (substituted) C1-10 alkyl, alkenyl, alkynyl, but R2 ≠ 2-octenyl, 8-acetoxy-2-octenyl, 2,5-octadienyl; R3 = H, protecting group], useful as antitumor agents, are prepared from II (R5R6 = bond). Treatment of II (X = Cl; R2 = 3,7-dimethyloctyl; R3 = Me3Si; R5R6 = bond) (preparation given) with LDA/THF at -45°, followed by addition of MeO2C(CH2)5CHO in THF at -45° gave 50% I (X = Cl; A = H; B = OH; R1 = MeO2C(CH2)2; R2 = 3,7-dimethyloctyl; R3 = Me3Si), which in pyridine was treated with MsCl, followed by addition of DBU to afford 30% (Z)-I (AB = bond) (III) and 52% (E)-III. (E)-III showed IC50 of 0.025 μg/mL against leukemia L1210 cells.

IT 104248-48-8P 104248-51-3P 104248-75-1P
114499-39-7P 114521-75-8P 114531-78-1P
114531-79-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as antitumor agent)

RN 104248-48-8 HCAPLUS
CN 3-Cyclopentene-1-heptanoic acid, 3-chloro-5-[3-(3,4-

dimethoxyphenyl)propyl]-ζ,5-dihydroxy-2-oxo-, methyl ester (CA INDEX NAME)



RN 104248-51-3 HCAPLUS
CN Heptanoic acid, 7-[4-chloro-2-[3-(3,4-dimethoxyphenyl)propyl]-2-hydroxy-5-oxo-3-cyclopenten-1-ylidene]-, methyl ester (CA INDEX NAME)



RN 104248-75-1 HCAPLUS
CN 2-Cyclopenten-1-one, 2-chloro-5-(3,7-dimethyl-2,6-octadien-1-ylidene)-4-hydroxy-4-(4-phenoxybutyl)- (CA INDEX NAME)



RN 114499-39-7 HCAPLUS
CN 2-Cyclopenten-1-one, 2-chloro-5-(4,7-dihydroxy-2-hepten-1-ylidene)-4-hydroxy-4-(4-phenoxybutyl)- (CA INDEX NAME)



RN 114531-75-8 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 114531-78-1 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 10-chloro-12-hydroxy-15,19-dimethyl-9-oxo-, methyl ester, (7Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 114531-79-2 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 10-chloro-12-hydroxy-15,19-dimethyl-9-oxo-, methyl ester, (7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 22 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:454513 HCAPLUS Full-text
DOCUMENT NUMBER: 109:54513
ORIGINAL REFERENCE NO.: 109:9183a,9186a

TITLE: Total syntheses of clavulones and punaglandins
AUTHOR(S): Sasai, Hiroaki; Ogawa, Yuji; Iwasaki, Genji; Sano, Mami; Sodeoka, Mikiko; Shibasaki, Masakatsu
CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Japan
SOURCE: Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1987), 29, 409-16
CODEN: TYKYDS
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
ED Entered STN: 19 Aug 1988
AB A report from a symposium describing the total syntheses of marine eicosanoids (+)-clavulone II and (+)-punaglandin 4.
IT 96055-66-2P, (+)-Punaglandin 4
RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of)
RN 96055-66-2 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 23 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:437539 HCAPLUS Full-text
DOCUMENT NUMBER: 109:37539
ORIGINAL REFERENCE NO.: 109:6346h,6347a
TITLE: Preparation of 5-(carboxyalkenyl)-2-halo-4-hydroxy-2-cyclopentenones as antitumor agents
INVENTOR(S): Nakamoto, Yasumasa; Ishizuka, Yoriyasu; Miyamura, Yoshio; Togashi, Masahiro; Nagai, Zene; Tsuji, Shunichi; Morikawa, Susumu
PATENT ASSIGNEE(S): Nihon Iyakuhin Kogyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62129245	A	19870611	JP 1985-268397	19851130 <--
PRIORITY APPLN. INFO.:			JP 1985-268397	19851130 <--

OTHER SOURCE(S): CASREACT 109:37539
ED Entered STN: 05 Aug 1988
GI



I

AB The title compds. [I; X = halo; R = H, CO2R3; R3 = (unbranched) alkyl, cycloalkyl, (unsubstituted) Ph; R1 = H, lower alkyl; R2 = H, protecting group; R4 = OH or H where C-5 and C-1' are linked with a double or single bond resp.; A = CH2, O, S], useful as antitumor agents, were prepared A solution of 2-chloro-4-hydroxy-4-methoxycarbonyl-2-cyclopentenone in THF was added dropwise at -60° to a mixture of Me3SiNHSiMe3 and BuLi in THF and after 20 min, Bu3SnCl was added, followed by warming to -20°. A solution of OHC(CH2)5CO2Me in THF was added at -60° and the mixture was stirred for 30 min to give 76% I (X = Cl, R = CO2Me, R1 = Me, R2 = H, R4 = OH; C-2' and C-3' being linked with a double bond; A = CH2) which was treated with MeSO2Cl in CH2Cl2 containing Et3N to give 25.6% I (R4 = H, other variables as defined above) (II). II inhibited the growth of L1210 mouse leukemia cells with an IC50 of 0.05 μg/mL.

IT 107836-95-3P 107836-96-4P 114011-01-7P
114011-02-8P 114011-03-9P 114011-04-0P
114011-05-1P 114011-06-2P 114011-14-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antitumor agent)

RN 107836-95-3 HCAPLUS

CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl)-4-oxo-, methyl ester (CA INDEX NAME)



RN 107836-96-4 HCAPLUS

CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(7-methoxy-7-oxo-2-hepten-1-ylidene)-4-oxo-, methyl ester (CA INDEX NAME)



RN 114011-01-7 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-fluoro-1-hydroxy-5-[1-hydroxy-4-(2-methoxy-2-oxoethoxy)butyl]-4-oxo-, methyl ester (CA INDEX NAME)



RN 114011-02-8 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-fluoro-1-hydroxy-5-[4-(2-methoxy-2-oxoethoxy)butylidene]-4-oxo-, methyl ester (CA INDEX NAME)



RN 114011-03-9 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-fluoro-1-hydroxy-5-(1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl)-4-oxo-, methyl ester (CA INDEX NAME)



RN 114011-04-0 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-fluoro-1-hydroxy-5-(7-methoxy-7-oxo-2-hepten-1-ylidene)-4-oxo-, methyl ester (CA INDEX NAME)



RN 114011-05-1 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-bromo-1-hydroxy-5-(1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl)-4-oxo-, methyl ester (CA INDEX NAME)



RN 114011-06-2 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-bromo-1-hydroxy-5-(7-methoxy-7-oxo-2-hepten-1-ylidene)-4-oxo-, methyl ester (CA INDEX NAME)



RN 114011-14-2 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-[4-[(2-methoxy-2-oxoethyl)thio]butylidene]-4-oxo-, methyl ester (CA INDEX NAME)



L43 ANSWER 24 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:422686 HCAPLUS Full-text
DOCUMENT NUMBER: 109:22686
ORIGINAL REFERENCE NO.: 109:3865a,3868a
TITLE: Synthetic studies on marine prostanoids
AUTHOR(S): Kosugi, Hirafumi; Watanabe, Yasuyuki; Konta, Hiroshi; Uda, Hisashi
CORPORATE SOURCE: Chem. Res. Inst. Non-Aqueous Solutions, Tohoku Univ., Japan
SOURCE: Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1987), 29, 417-24

CODEN: TYKYDS
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
ED Entered STN: 22 Jul 1988
AB A report from a symposium describing the total synthesis of marine prostanoids clavulone II, clavulone III, and chlorovulone II.
IT 100295-80-5P, Chlorovulone II
RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of)
RN 100295-80-5 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 25 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:406130 HCAPLUS Full-text
DOCUMENT NUMBER: 109:6130
ORIGINAL REFERENCE NO.: 109:1153a,1156a
TITLE: A process for the preparation of 3-fluoro-4-hydroxy-2-cyclopentenone derivatives as intermediates for fluoropunaglandins
INVENTOR(S): Hasato, Atsuo; Kurozumi, Seiji; Suzuki, Masaaki; Noyori, Ryoji
PATENT ASSIGNEE(S): Teijin Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62242640	A	19871023	JP 1986-84961	19860415 <--
JP 06004555	B	19940119		
PRIORITY APPLN. INFO.:			JP 1986-84961	19860415 <--

ED Entered STN: 09 Jul 1988
GI

I

AB The title compds. [I; X = F; R = H, tri(C1-7 alkyl)silyl, or forming an acetal], 4R-, 4S-I or their mixts., useful as intermediates for fluorinated punaglandins and other 5-membered ring compds., were prepared A solution of KF and 18-crown-6 ether was stirred 30 min, I (X = Cl, R = tetrahydropyranyl) was added, and the mixture was stirred 12 h at room temperature to give 25% I (X = F, R = tetrahydropyranyl).

IT 96055-66-2D, fluorinated
RL: RCT (Reactant); RACT (Reactant or reagent)
(intermediate for, fluorohydroxycyclopentenone derivative as)

RN 96055-66-2 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 26 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:221488 HCAPLUS Full-text
DOCUMENT NUMBER: 108:221488
ORIGINAL REFERENCE NO.: 108:36350h,36351a
TITLE: Preparation of punaglandin derivatives
INVENTOR(S): Noyori, Ryoji; Suzuki, Masaaki; Morita, Yasushi; Yanagisawa, Akira
PATENT ASSIGNEE(S): Teijin Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62207254	A	19870911	JP 1986-48516	19860307 <--
JP 06055716	B	19940727		
PRIORITY APPLN. INFO.:			JP 1986-48516	19860307 <--

ED Entered STN: 24 Jun 1988
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I (R1 = C1-10 alkyl; R2 = H, OH-protecting group; A is H, B is OH, or AB = bond; * indicates asym. C), II, and III, useful as potential anticancer and antiviral agents, were prepared from IV and V. Condensation of enone VI (preparation given) and aldehyde VII (preparation given), followed by dehydration of the product, gave 37% dienone VIII.

IT 105927-55-7P 105927-56-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as potential anticancer and antiviral agent)

RN 105927-55-7 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105927-56-8 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 27 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1988:186211 HCAPLUS Full-text
DOCUMENT NUMBER:	108:186211
ORIGINAL REFERENCE NO.:	108:30575a,30578a
TITLE:	Preparation of 2-halo-2-cyclopenten-1-one derivatives as antitumor agents
INVENTOR(S):	Nakamoto, Yasumasa; Ishizuka, Yoriyasu; Miyamura, Yoshio; Togashi, Masahiro; Nagai, Zene; Tsuji, Shunichi; Morikawa, Susumu
PATENT ASSIGNEE(S):	Nihon Iyakuhin Kogyo Co., Ltd., Japan
SOURCE:	Jpn. Kokai Tokkyo Koho, 23 pp. CODEN: JKXXAF
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62114933	A	19870526	JP 1985-252825	19851113 <--
PRIORITY APPLN. INFO.:			JP 1985-252825	19851113 <--

ED Entered STN: 28 May 1988
GI



AB The title compds. (I; X = halo; R1 = H, alkyl; R2 = acyloxy; R4 = H, OH-protecting group; R = alkyl, CO2R3; R3 = alkyl, cycloalkyl, PhCH2; Q = H on unsatd., OH on saturated bond) and their pharmaceutically acceptable salts, useful as antitumor agents, are prepared To a mixture of 0.41 mL (Me3Si)2NH in THF and 10% LiBu in hexane at -50°, were successively added at -60° with stirring 0.408 g cyclopentenone II [X = Cl, R = Me, R4 = tetrahydropyranyl (THP)] in THF, 0.504 mL Bu3SnCl in THF, and then 0.380 g formylhexenoate (4R)-III (R1 = Me, R2 = AcO) in THF at -65° to -20° and the resulting mixture was treated with 30 mL saturated aqueous NH4Cl at 0° to give 0.230 g I (X = Cl, R = R1 = Me, R2 = AcO, R4 = THP, Q = H), which (0.220 g) in DME was deprotected with a drop of 6N HCl at 25° to give 0.064 g I (X = Cl, R = R1 = Me, R2 = AcO, R4 = H, Q = H) which showed IC50 of 0.04 μg/mL against L-1210 mouse leukemia cells.

IT 113922-70-6P 113922-71-7P 113922-72-8P
113922-73-9P 113922-74-0P 113947-25-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as neoplasm inhibitor)

RN 113922-70-6 HCAPLUS
CN 5-Heptenoic acid, 4-(acetyloxy)-7-(4-chloro-2-hydroxy-2-methyl-5-oxo-3-cyclopenten-1-ylidene)-, methyl ester (CA INDEX NAME)



RN 113922-71-7 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 5-[4-(acetyloxy)-7-methoxy-7-oxo-2-

hepten-1-ylidene]-3-chloro-1-hydroxy-4-oxo-, methyl ester (CA INDEX NAME)



RN 113922-72-8 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 5-[4-(acetyloxy)-1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl]-3-fluoro-1-hydroxy-4-oxo-, methyl ester (CA INDEX NAME)



RN 113922-73-9 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 5-[4-(acetyloxy)-7-methoxy-7-oxo-2-hepten-1-ylidene]-3-fluoro-1-hydroxy-4-oxo-, methyl ester (CA INDEX NAME)



RN 113922-74-0 HCAPLUS
CN 5-Heptenoic acid, 4-(acetyloxy)-7-(4-chloro-2-hydroxy-2-methyl-5-oxo-3-cyclopenten-1-ylidene)- (CA INDEX NAME)



RN 113947-25-4 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 5-[4-(acetyloxy)-1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl]-3-chloro-1-hydroxy-4-oxo-, methyl ester (CA INDEX NAME)



L43 ANSWER 28 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:180821 HCAPLUS Full-text
DOCUMENT NUMBER: 108:180821
ORIGINAL REFERENCE NO.: 108:29560h,29561a
TITLE: In vivo effects of prostaglandins on human retinoblastoma cells in nude mice
AUTHOR(S): Nakamura, Masao; Fujino, Yujiro; Mochizuki, Manabu; Minoda, Kensei; Masuda, Kenjiro
CORPORATE SOURCE: Sch. Med., Univ. Tokyo, Tokyo, 113, Japan
SOURCE: Japanese Journal of Ophthalmology (1987), 31(4), 608-20
CODEN: JJOPA7; ISSN: 0021-5155
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 28 May 1988
GI



I

AB PGD2 and 64 E (I), a prostaglandin derivative, were tested for their capacity to suppress the growth of retinoblastoma in the nude mouse. Ten million cells of an established cell line of human retinoblastoma, Y-79 cells, were transferred s.c. into the nude mouse, and after the transferred cells became a tumor with a diameter >7.5 mm, either PGD2 (1, 2, or 4 mg/kg/day) or I (4 mg/kg/day) dissolved in Hanks' solution was daily injected s.c. near the tumor for 14 days. The estimated tumor weight as defined by the formula of (length) + (width)2/2 was evaluated at various time intervals after the treatment. Although a low dose of PGD2, 1 mg/kg/day, had no effect, higher doses of PGD2 had a clear effect in suppressing the growth of retinoblastoma in the nude mouse. Tumors in I-treated animals were also markedly suppressed in their growth. Histol. examination revealed that tumors treated with these drugs had a much larger area of necrosis with fewer tumor cells than the tumors in control animals.

IT 114247-16-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor activity of, in retinoblastoma of human)
RN 114247-16-4 HCAPLUS
CN Prosta-5,7,10-trien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7E,12α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 29 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:180820 HCAPLUS Full-text
DOCUMENT NUMBER: 108:180820
ORIGINAL REFERENCE NO.: 108:29557a,29560a
TITLE: In vitro effects of prostaglandins on human retinoblastoma cell line Y-79 cells
AUTHOR(S): Nakamura, Masao; Koshihara, Yasuko; Fujino, Yujiro; Mochizuki, Manabu; Minoda, Kensei; Masuda, Kanjiro
CORPORATE SOURCE: Sch. Med., Univ. Tokyo, Tokyo, 113, Japan
SOURCE: Japanese Journal of Ophthalmology (1987), 31(4), 598-607
CODEN: JJOPA7; ISSN: 0021-5155
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 28 May 1988
GI



I

AB An established retinoblastoma cell line, Y-79, was investigated for its capacity to synthesize prostaglandins (PGs) and its susceptibility to PGs and their derivs., 64 E (I), exogenously given. The capacity of Y-79 cells to produce PGs was estimated by TLC using [1-14C] arachidonic acid as a substrate, and it was found that no detectable amts. of PGD2, PGE2, PGF2α, thromboxane B2, or 6-keto PGF1α were produced by Y-79 cells. Furthermore, the effect of exogenously given PGs (PGA1, A2, D2 E1, E2, F2α, and J2) and I on the cell proliferation of Y-79 cells in culture were examined PGE1, E2, and

F2α showed no effects on the cell growth of Y-79 cells at all tested doses (1-20 μg/mL). On the other hand, PGA1, A2, D2, and J2, and I remarkably inhibited the growth of Y-79 cells. A dose-response study indicated that I was the most effective among these drugs, followed by PGJ2. PGD2, A1, and A2 were less effective than PGJ2. Thus, Y-79 cells do not produce endogenous PGs, and these cells are highly susceptible to exogenous PGs (PGJ2, D2, A1, and A2) as well as I.

IT 114247-16-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor activity of, in retinoblastoma of human)
RN 114247-16-4 HCAPLUS
CN Prosta-5,7,10-trien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7E,12α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 30 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:112018 HCAPLUS Full-text
DOCUMENT NUMBER: 108:112018
ORIGINAL REFERENCE NO.: 108:18329a,18332a
TITLE: Total synthesis of punaglandin 4
AUTHOR(S): Sasai, Hiroaki; Shibasaki, Masakatsu
CORPORATE SOURCE: Sagami Chem. Res. Cent., Sagamihara, Japan
SOURCE: Tetrahedron Letters (1987), 28(3), 333-6
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:112018
ED Entered STN: 01 Apr 1988
GI



AB The marine prostanoid, punaglandin 4 (I) was prepared from 1,2-bis(trimethylsiloxy)cyclopentene. In a key sequence, diol II [R = cis-CH2CH:CH(CH2)4Me, R1 = H] was selectively mesylated to give II (R1 = MeSO2). Upon solvolysis in aqueous DMSO, II (R1 = MeSO2) underwent rearrangement to give the isomeric diol III (same R) as a 1:1 mixture of epimers.

IT 96055-68-4P 105927-55-7P 105927-56-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 96055-68-4 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105927-55-7 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105927-56-8 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 96055-66-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of)
RN 96055-66-2 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 31 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:55688 HCAPLUS Full-text
DOCUMENT NUMBER: 108:55688
ORIGINAL REFERENCE NO.: 108:9289a,9292a
TITLE: Prostaglandin synthesis 15. Synthesis and structural revision of (7E)- and (7Z)-punaglandin 4
AUTHOR(S): Suzuki, Masaaki; Morita, Yasushi; Yanagisawa, Akira; Baker, Bill J.; Scheuer, Paul J.; Noyori, Ryoji
CORPORATE SOURCE: Dep. Chem., Nagoya Univ., Nagoya, 464, Japan
SOURCE: Journal of Organic Chemistry (1988), 53(2), 286-95
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:55688
ED Entered STN: 20 Feb 1988
GI



I

II

AB A convergent synthesis of antineoplastic (7E)- and (7Z)-punaglandin 4, dictates revision of the originally postulated structures, to the stereoisomers, (7E)- and (7Z)-I, resp. Condensation of (R)-3-chloro-4-(tert-butyldimethylsiloxy)-2-cyclopentenone and the Li derivative of CH2:C:C(SnMe3)(CH2)4Me gave after desilylation the crystalline acetylenic diol II. Partial hydrogenation of the triple bond using Lindlar catalyst, followed by oxidation of the secondary alc. with pyridinium dichromate gave the hydroxy enone. The punaglandin skeleton was constructed by aldol condensation of the silyl-protected hydroxycyclopentenone and (2R,3S)-2,3-diacetoxy-6-carbomethoxyhexanal. Dehydration of the aldol product followed by desilylation gave (7E)- and (7Z)-I identical with the naturally occurring sample in all respects. The enantiomers and some other stereoisomers were prepared and exhibit similar inhibitory effects on L1210 leukemia cell proliferation.

IT 103384-65-2P 103384-66-3P 103384-67-4P
103384-68-5P 103531-36-8P 105927-55-7P
105927-56-8P 111901-59-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antitumor activity of)

RN 103384-65-2 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5R,6R,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 103384-66-3 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5R,6R,7Z,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 103384-67-4 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 103384-68-5 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7Z,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 103531-36-8 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105927-55-7 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105927-56-8 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 111901-59-8 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 96055-66-2P 96055-68-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation, photochem. isomerization, and antitumor activity of)
RN 96055-66-2 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-68-4 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 32 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:35031 HCAPLUS Full-text
DOCUMENT NUMBER: 108:35031
ORIGINAL REFERENCE NO.: 108:5809a,5812a

TITLE: A new marine epoxy prostanoid with an antiproliferative activity from the stolonifer Clavularia viridis Quoy and Gaimard
AUTHOR(S): Iguchi, Kazuo; Kaneta, Soichiro; Mori, Kenichiro; Yamada, Yasuji
CORPORATE SOURCE: Tokyo Coll. Pharm., Hachioji, 192-03, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1987), 35(10), 4375-6
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 06 Feb 1988
GI



I

AB A new marine epoxy prostanoid (I) with an antiproliferative activity was isolated from the Japanese stolonifer C. viridis. The structure of I was established on the basis of spectroscopy and chemical transformation.
IT 100295-81-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(epoxidn. of)
RN 100295-81-6 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 33 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:214 HCAPLUS Full-text
DOCUMENT NUMBER: 108:214
ORIGINAL REFERENCE NO.: 108:31a,34a
TITLE: Antiproliferative and cytotoxic effects of newly discovered halogenated coral prostanoids from the Japanese stolonifer Clavularia viridis on human myeloid leukemia cells in culture
AUTHOR(S): Honda, Atsushi; Mori, Yo; Iguchi, Kazuo; Yamada, Yasuji

CORPORATE SOURCE: Dep. Biochem., Tokyo Coll. Pharm., Hachioji, 192-03, Japan
SOURCE: Molecular Pharmacology (1987), 32(4), 530-5
CODEN: MOPMA3; ISSN: 0026-895X
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 09 Jan 1988
AB The antiproliferative and cytotoxic activities of newly discovered halogenated coral prostanoids (chlorovulone, bromovulone, and iodovulone) from the Japanese stolonifer C. viridis and their related compds. were determined in HL-60 cells in culture. The order of antiproliferative and cytotoxic activities of naturally occurring marine prostanoids against HL-60 cells was chlorovulone I > bromovulone I = iodovulone I > clavulone I or II > PGA2. The IC50 (concentration required to inhibit cell growth by 50%) value (0.03 μM (0.01 μg/mL)) and cytotoxic effects (>0.3 μM (0.1 μg/mL)) of chlorovulone I were about 200 and 100 times stronger than those of PGA2, resp., on the molar basis. From the data on the structure-activity relationship of the halogenated coral prostanoids and the related compds., it was determined that the alkylidencyclopentenone structure in these prostanoids was essential for the antiproliferative and cytotoxic activities against HL-60 cells and the introduction of halogen function at C-10 position in the structure enhanced the activities (Cl = F > Br = I > H), that the stereospecificity of the 12-hydroxyl group in the chlorovulone mol. was not required for the activities, and that the presence of dienone (C5-6 and C7-8) in the structure potentiated the activities. Bivariate DNA/bromodeoxyuridine anal. with a flow cytometer showed that chlorovulone I transiently arrested the cell cycle progression from G1 to S after 24-h exposure to the nontoxic concns. (0.03 and 0.09 μM) and caused the lasting blockade of leukemia cells in G1 at the cytotoxic concentration Apparently, these coral prostanoids and related compds. may be a promising antileukemic agent.
IT 100295-81-6, Chlorovulone I 105343-03-1, Iodovulone I
105343-04-2, Bromovulone I 105560-77-8, (-)-Chlorovulone II 111695-42-2 111695-43-3
RL: BIOL (Biological study)
(leukemia from human growth inhibition by)
RN 100295-81-6 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105343-03-1 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 12-hydroxy-10-iodo-9-oxo-, methyl ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105343-04-2 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-bromo-12-hydroxy-9-oxo-, methyl ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105560-77-8 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 111695-42-2 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 4-(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (4R,5E,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 111695-43-3 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 4-(acetyloxy)-10-fluoro-12-hydroxy-9-oxo-, methyl ester, (4R,5E,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 34 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:439505 HCAPLUS Full-text
DOCUMENT NUMBER: 107:39505
ORIGINAL REFERENCE NO.: 107:6599a,6602a
TITLE: Preparation of punaglandin derivatives
INVENTOR(S): Noyori, Ryoji; Suzuki, Masaaki; Kurozumi, Seiji
PATENT ASSIGNEE(S): Teijin Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62059258	A	19870314	JP 1985-197688	19850909 <--
PRIORITY APPLN. INFO.:			JP 1985-197688	19850909 <--

OTHER SOURCE(S): CASREACT 107:39505
ED Entered STN: 08 Aug 1987
GI



I



II

AB Punaglandin derivs. (I; R1 = C1-10 alkyl; R2 = H, protecting group; A = H when B = OH, AB = bond), useful as anticancer and antiviral agents, are prepared (Me2CH)2NLi (0.4M) in THF was added to a solution of 0.36 mmol enone derivative II in THF at -78°, followed by 0.37 mmol HCOCH(OAc)CH(OAc)(CH2)3CO2Me in THF, cooled to -95°, and adjusted to pH 7.4 with phosphate buffer to give a mixture of 2 diastereomers I (A = H, B = OH, R1 = Me, R2 = Me3Si) in 13% and 4% yield, resp., which was dehydrated to give 37% dienone derivative I (AB = bond, R1 = Me, R2 = Me3Si) (III). Hydrolysis of 1.8 mg III in HOAc-H2O-THF at 0-30° gave a mixture of 0.5 mg (E)- and 0.8 mg (Z)-I (AB = bond, R1 = Me, R2 = H; isomeric about C-7-8).

IT 105927-55-7P 105927-56-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as anticancer and antiviral agent)

RN 105927-55-7 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105927-56-8 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 35 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:423115 HCAPLUS Full-text
DOCUMENT NUMBER: 107:23115
ORIGINAL REFERENCE NO.: 107:3899a,3902a
TITLE: Synthesis of antitumor marine prostanoids
AUTHOR(S): Nagaoka, Hiroto; Yamada, Yasuji
CORPORATE SOURCE: Tokyo Coll. Pharm., Hachioji, 192-03, Japan

SOURCE: Yuki Gosei Kagaku Kyokaishi (1986), 44(12), 1145-54
CODEN: YGKKAE; ISSN: 0372-770X
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese
ED Entered STN: 25 Jul 1987
AB A review with 27 refs. (mostly since 1980) on synthesis of antitumor marine prostamoids, clavulones, chlorovulones, and punaglandins 3 and 4.
IT 96055-65-1P, Punaglandin 3 96055-66-2P, Punaglandin 4
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of)
RN 96055-65-1 HCAPLUS
CN Prosta-7,10,14,17-tetraen-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-66-2 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 36 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:175830 HCAPLUS Full-text
DOCUMENT NUMBER: 106:175830
ORIGINAL REFERENCE NO.: 106:28525a,28528a
TITLE: 2-Halo-2-cyclopentenone derivatives as antitumor agents
INVENTOR(S): Nakamoto, Yasumasa; Ishizuka, Yoriyasu; Miyamura, Yoshio; Togashi, Masahiro; Nagai, Zene; Tsuji, Shunichi; Morikawa, Susumu
PATENT ASSIGNEE(S): Nihon Iyakuhin Kogyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62000044	A	19870106	JP 1985-136767	19850625 <--
PRIORITY APPLN. INFO.:			JP 1985-136767	19850625 <--

ED Entered STN: 29 May 1987
GI



I

II

AB 2-Halo-2-cyclopentenone derivs. (I; X = halo; R = alkyl, alkoxycarbonyl, etc.; R1 = H, alkyl; R2 = H, alkyl, protecting group; Q = OH with single bond, H with double bond), useful as antitumor agents, are prepared Cyclopentenone derivative II in THF was treated with BuLi in hexane and hexamethyldisilazane in THF at −70 to −20°. Bu3SnCl and Me 7-oxo-5-heptenoate in THF at -60 to -55° were added to give 43.8% I (X = Cl, R = Et, R1 = Me, R2 = H, Q = OH, single bond). In vitro screening tests using L1210 mouse leukemia cells showed that I had IC50 values ranging from 0.04-2.70 μg/mL.

IT 107836-91-9P 107836-92-0P 107836-93-1P
107836-94-2P 107836-95-3P 107836-96-4P
107836-98-6P 107836-99-7P 107837-01-4P
107837-02-5P 107837-03-6P 107837-04-7P
107837-08-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antitumor agent)

RN 107836-91-9 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl)-4-oxo-, ethyl ester (CA INDEX NAME)



RN 107836-92-0 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(7-methoxy-7-oxo-2-hepten-1-ylidene)-4-oxo-, ethyl ester (CA INDEX NAME)



RN 107836-93-1 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl)-4-oxo-, butyl ester (CA INDEX NAME)



RN 107836-94-2 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(7-methoxy-7-oxo-2-hepten-1-ylidene)-4-oxo-, butyl ester (CA INDEX NAME)



RN 107836-95-3 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl)-4-oxo-, methyl ester (CA INDEX NAME)



RN 107836-96-4 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(7-methoxy-7-oxo-2-hepten-1-ylidene)-4-oxo-, methyl ester (CA INDEX NAME)



RN 107836-98-6 HCAPLUS
CN Prosta-5,7,10-trien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry unknown.



RN 107836-99-7 HCAPLUS
CN Prosta-5,7,10-trien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, (12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry unknown.



RN 107837-01-4 HCAPLUS
CN 5-Heptenoic acid, 7-(2-butyl-4-chloro-2-hydroxy-5-oxo-3-cyclopenten-1-ylidene)-, methyl ester (CA INDEX NAME)



RN 107837-02-5 HCAPLUS

CN 5-Heptenoic acid, 7-(2-butyl-4-chloro-2-hydroxy-5-oxo-3-cyclopenten-1-ylidene)- (CA INDEX NAME)



RN 107837-03-6 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl)-4-oxo-, phenylmethyl ester (CA INDEX NAME)



RN 107837-04-7 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(7-methoxy-7-oxo-2-hepten-1-ylidene)-4-oxo-, phenylmethyl ester (CA INDEX NAME)



RN 107837-08-1 HCAPLUS
CN 5-Heptenoic acid, 7-(4-chloro-2-hydroxy-2-methyl-5-oxo-3-cyclopenten-1-ylidene)-, methyl ester (CA INDEX NAME)



IT 107836-91-9P 107836-93-1P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as intermediate for antitumor cyclopentenone derivs.)

RN 107836-91-9 HCAPLUS

CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl)-4-oxo-, ethyl ester (CA INDEX NAME)



RN 107836-93-1 HCAPLUS

CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl)-4-oxo-, butyl ester (CA INDEX NAME)



IT 107836-95-3P 107836-98-6P 107837-01-4P
107837-03-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for antitumor halocyclopentenones)

RN 107836-95-3 HCAPLUS

CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl)-4-oxo-, methyl ester (CA INDEX NAME)



RN 107836-98-6 HCAPLUS

CN Prosta-5,7,10-trien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry unknown.



RN 107837-01-4 HCAPLUS
CN 5-Heptenoic acid, 7-(2-butyl-4-chloro-2-hydroxy-5-oxo-3-cyclopenten-1-ylidene)-, methyl ester (CA INDEX NAME)



RN 107837-03-6 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(1-hydroxy-7-methoxy-7-oxo-2-hepten-1-yl)-4-oxo-, phenylmethyl ester (CA INDEX NAME)



L43 ANSWER 37 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:119344 HCAPLUS Full-text
DOCUMENT NUMBER: 106:119344
ORIGINAL REFERENCE NO.: 106:19486h,19487a
TITLE: 2-Halo-5-(6-carboxyhexylidene)-2-cyclopentenone analogs
INVENTOR(S): Nakamoto, Yasumasa; Ishizuka, Yoriyasu; Miyamura, Yoshio; Togashi, Masahiro; Fujii, Masahiro; Kato, Yuichi; Nagai, Zene; Tsuji, Shunichi; Morikawa, Susumu; Ohira, Yutaka
PATENT ASSIGNEE(S): Nihon Iyakuhin Kogyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 61205230	A	19860911	JP 1985-45735	19850309 <--
PRIORITY APPLN. INFO.:			JP 1985-45735	19850309 <--

ED Entered STN: 17 Apr 1987
GI



I



III

AB The title compds. [I; R = alkyl, alkoxycarbonyl; R1 = H, lower alkyl; R2 = H, acyl, tetrahydropyran-2-yl (THP), tetrahydrofuran-2-yl; X = halo; Z = CH2, O, S], useful as anticancer agents, were prepared via aldol condensation of 2-halo-2-cyclopentenone derivs. with OHC(CH2)3ZCH2CO2R1 (II; R1 = lower alkyl) and dehydration of the resulting cyclopentenone derivs. III. Thus, a solution of 4-n-butyl-2-chloro-4-(tetrahydropyran-2- yloxy)-2-cyclopentenone in THF was added dropwise at −55° to a mixture of Me3SiNHSiMe3 and n-BuLi in THF and after 0.5 h at −30°, II (Z = O; R1 = Me) in THF was added to the mixture The resulting mixture was allowed to react at −50° to −30° for 1 h to give 35.6% III (R = H, R1 = Me, R2 = THP, X = Cl, Z = O). Treatment of this with MeSO2Cl in CH2Cl containing Et3N at room temperature for 1 h gave 40% I (R = H, R1 = Me, R2 = THP, X = Cl, Z = O). I at 0.06-0.10 μg/mL in vitro inhibited by 50% the growth of mouse leukemia cells L1210.

IT 107008-54-8P 107032-64-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dehydration of)

RN 107008-54-8 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-[1-hydroxy-4-(2-methoxy-2-oxoethoxy)butyl]-4-oxo-, methyl ester (CA INDEX NAME)



RN 107032-64-4 HCAPLUS
CN 3-Cyclopentene-1-heptanoic acid, 3-chloro-ζ,5-dihydroxy-5-(methoxycarbonyl)-2-oxo-, methyl ester (CA INDEX NAME)



IT 102355-12-4P 107008-39-9P 107008-40-2P
107008-46-8P 107008-49-1P 107008-51-5P
107008-52-6P 107008-53-7P 107008-55-9P
107008-57-1P 107008-59-3P 107008-61-7P
107008-62-8P 107008-77-5P 107032-62-2P
107032-63-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as anticancer agent)

RN 102355-12-4 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (7E,12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107008-39-9 HCAPLUS
CN Acetic acid, [4-(2-butyl-4-chloro-2-hydroxy-5-oxo-3-cyclopenten-1-ylidene)butoxy]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107008-40-2 HCAPLUS
CN Acetic acid, [4-(2-butyl-4-chloro-2-hydroxy-5-oxo-3-cyclopenten-1-ylidene)butoxy]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107008-46-8 HCAPLUS
CN Heptanoic acid, 7-(2-butyl-4-chloro-2-hydroxy-5-oxo-3-cyclopenten-1-ylidene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107008-49-1 HCAPLUS
CN Heptanoic acid, 7-(4-chloro-2-hydroxy-2-methyl-5-oxo-3-cyclopenten-1-ylidene)-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107008-51-5 HCAPLUS
CN Acetic acid, [4-(4-chloro-2-hydroxy-2-methyl-5-oxo-3-cyclopenten-1-ylidene)butoxy]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107008-52-6 HCAPLUS
CN Acetic acid, [4-(4-chloro-2-hydroxy-2-methyl-5-oxo-3-cyclopenten-1-ylidene)butoxy]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107008-53-7 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-(7-methoxy-7-oxoheptylidene)-4-oxo-, methyl ester (CA INDEX NAME)



RN 107008-55-9 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-[4-(2-methoxy-2-oxoethoxy)butylidene]-4-oxo-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107008-57-1 HCAPLUS
CN Acetic acid, [[4-(4-chloro-2-hydroxy-2-octyl-5-oxo-3-cyclopenten-1-ylidene)butyl]thio]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107008-59-3 HCAPLUS
CN Acetic acid, [4-(4-chloro-2-hydroxy-2-octyl-5-oxo-3-cyclopenten-1-ylidene)butoxy]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107008-61-7 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-[4-[(2-methoxy-2-oxoethyl)thio]butylidene]-4-oxo-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107008-62-8 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-[4-[(2-methoxy-2-oxoethyl)thio]butylidene]-4-oxo-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107008-77-5 HCAPLUS
CN 2-Cyclopentene-1-carboxylic acid, 3-chloro-1-hydroxy-5-[4-(2-methoxy-2-oxoethoxy)butylidene]-4-oxo-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107032-62-2 HCAPLUS
CN Acetic acid, [[4-(2-butyl-4-chloro-2-hydroxy-5-oxo-3-cyclopenten-1-ylidene)butyl]thio]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 107032-63-3 HCAPLUS
CN Heptanoic acid, 7-(4-chloro-2-hydroxy-2-methyl-5-oxo-3-cyclopenten-1-ylidene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L43 ANSWER 38 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:13065 HCAPLUS Full-text
DOCUMENT NUMBER: 106:13065
ORIGINAL REFERENCE NO.: 106:2157a,2160a
TITLE: Antitumor eicosanoids: natural occurrence and drug design
AUTHOR(S): Fukushima, M.
CORPORATE SOURCE: Dep. Intern. Med., Aichi Cancer Cent., Nagoya, Japan
SOURCE: Recent Adv. Chemother., Proc. Int. Congr. Chemother., 14th (1985), Volume Anticancer Sect. 1, 25-7. Editor(s): Ishigami, Joji. Univ. Tokyo Press: Tokyo, Japan.
CODEN: 55GNAX
DOCUMENT TYPE: Conference
LANGUAGE: English
ED Entered STN: 24 Jan 1987
AB The antitumor activities of alkylidenecyclopentenone prostaglandins, such as Δ7-PGA1 [92340-58-4] and Δ12-13,14-dihydro-PGJ2 [97588-64-2], and the marine eicosanoids, clavilones and prostaglandins, were compared and structure-activity relations were determined The results indicated that the cyclopentenone ring was required for antitumor activity, and cytotoxicity could be potentiated by the presence of 10-Cl and 12-OH groups. Both 10-Cl and 12-OH groups were required to produce full cytotoxicity. The cytotoxicity of 10-Cl,12-OH-Δ7-PGA1 [105801-34-1] was almost equal to that of vincristine or doxorubicin, and this structure may serve as the basis of a new class of antitumor agents.
IT 105801-34-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm-inhibiting activity of, structure in relation to)
RN 105801-34-1 HCAPLUS
CN Prosta-7,10,13-trien-1-oic acid, 10-chloro-12,15-dihydroxy-9-oxo-, (7E,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 39 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:4706 HCAPLUS Full-text
DOCUMENT NUMBER: 106:4706
ORIGINAL REFERENCE NO.: 106:879a,882a
TITLE: Studies on marine natural products. XIII. Determination of absolute configuration of chlorovulones by CD measurement and by enantioselective synthesis of (-)-chlorovulone II
AUTHOR(S): Nagaoka, Hiroto; Iguchi, Kazuo; Miyakoshi, Tohru; Yamada, Nobuko; Yamada, Yasuji
CORPORATE SOURCE: Tokyo Coll. Pharm., Hachioji, 192-03, Japan
SOURCE: Tetrahedron Letters (1986), 27(2), 223-6
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 106:4706
ED Entered STN: 11 Jan 1987
GI



I

AB Absolute configuration of chlorovulones I-IV (I) new halogenated marine prostanoids with antitumor activity, isolated from the stolonifer Clavularia viridis Quoy and Gaimard, has been established on the basis of the CD measurements of chlorovulone derivs. and of the enantioselective synthesis of (-)-chlorovulone II (E,E-I).

IT 100201-69-2, Chlorovulone IV 100295-79-2, Chlorovulone III 100295-80-5, Chlorovulone II 100295-81-6, Chlorovulone I
RL: PRP (Properties)
(mol. structure of)

RN 100201-69-2 HCAPLUS

CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5Z,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 100295-79-2 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 100295-80-5 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 100295-81-6 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 105560-77-8P
RL: SPN (Synthetic preparation); PREP (Preparation)

(total synthesis of)
RN 105560-77-8 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 40 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:623048 HCAPLUS Full-text
DOCUMENT NUMBER: 105:223048
ORIGINAL REFERENCE NO.: 105:35963a,35966a
TITLE: Bromovulone I and iodovulone I, unprecedented brominated and iodinated marine prostanoids with antitumor activity isolated from the Japanese stolonifer Clavularia viridis Quoy and Gaimard
AUTHOR(S): Iguchi, Kazuo; Kaneta, Soichiro; Mori, Kenichiro; Yamada, Yasuji; Honda, Atsushi; Mori, Yo
CORPORATE SOURCE: Lab. Org. Chem., Tokyo Coll. Pharm., Tokyo, 192-03, Japan
SOURCE: Journal of the Chemical Society, Chemical Communications (1986), (12), 981-2
CODEN: JCCCAT; ISSN: 0022-4936
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 26 Dec 1986
GI



AB Bromovulone I and iodovulone I (I, R = Br or I, resp.), were isolated from Et2O exts. of C. viridis and their structures were determined by spectral means. Both compds. showed good antiproliferative and cytotoxic activity in human promyelocytic leukemia cells in vitro.
IT 105343-03-1 105343-04-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(from stolonifer, structure and antitumor activity of)
RN 105343-03-1 HCAPLUS

CN Prosta-5,7,10,14-tetraen-1-oic acid, 12-hydroxy-10-iodo-9-oxo-, methyl ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105343-04-2 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-bromo-12-hydroxy-9-oxo-, methyl ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 41 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:614107 HCAPLUS Full-text
DOCUMENT NUMBER: 105:214107
ORIGINAL REFERENCE NO.: 105:34437a,34440a
TITLE: Antiinflammatory method
INVENTOR(S): Mynderse, Jon S.; Bonjouklian, Rosanne
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4612330	A	19860916	US 1985-697997	19850204 <--
PRIORITY APPLN. INFO.:			US 1985-697997	19850204 <--

ED Entered STN: 13 Dec 1986
AB Punaglandin-1 and Punaglandin-2 are effective in treating inflammation and arthritis. The compds. may be administered by various routes including oral, rectal, transdermal, s.c., i.v., i.m., or intranasal. Thus, a hard gelatin capsule contained Punaglandin-1 250, dried starch 200; and Mg stearate 10 mg.
IT 96055-63-9 96055-64-0
RL: BIOL (Biological study)

(inflammation inhibitor)
RN 96055-63-9 HCAPLUS
CN Prosta-10,14,17-trien-1-oic acid, 5,6,7-tris(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7R,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-64-0 HCAPLUS
CN Prosta-10,14-dien-1-oic acid, 5,6,7-tris(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7R,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 42 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:572100 HCAPLUS Full-text
DOCUMENT NUMBER: 105:172100
ORIGINAL REFERENCE NO.: 105:27725a,27728a
TITLE: Prostaglandin synthesis. 12. Synthesis of (7E)- and (7Z)-punaglandin 4. Structural revision
AUTHOR(S): Suzuki, M.; Morita, Y.; Yanagisawa, A.; Noyori, R.; Baker, Bill J.; Scheuer, Paul J.
CORPORATE SOURCE: Dep. Chem., Nagoya Univ., Nagoya, 464, Japan
SOURCE: Journal of the American Chemical Society (1986), 108(16), 5021-2
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 105:172100
ED Entered STN: 15 Nov 1986
GI



I



II

AB Punaglandin 4 was shown to have structure I (and the Z isomer) by total synthesis of all relevant diastereoisomers and comparison with the natural product. The crystal structure of cyclopentenedione II was determined

IT 96055-66-2P 96055-68-4P 105927-55-7P
105927-56-8P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and absolute configuration of)

RN 96055-66-2 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-68-4 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105927-55-7 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 105927-56-8 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 103384-65-2P 103384-66-3P 103384-67-4P
103384-68-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of)
RN 103384-65-2 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5R,6R,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 103384-66-3 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5R,6R,7Z,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 103384-67-4 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 103384-68-5 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7Z,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 96055-66-2P 96055-68-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of, revision of punaglandin configuration in relation

to)
RN 96055-66-2 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-68-4 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 43 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:572099 HCAPLUS Full-text
DOCUMENT NUMBER: 105:172099
ORIGINAL REFERENCE NO.: 105:27725a,27728a
TITLE: Synthesis of punaglandin 3 and 4. Revision of the structures
AUTHOR(S): Nagaoka, Hiroto; Miyaoka, Hiroaki; Miyakoshi, Thu; Yamada, Yasuji
CORPORATE SOURCE: Tokyo Coll. Pharm., Tokyo, 192-03, Japan
SOURCE: Journal of the American Chemical Society (1986), 108(16), 5019-21
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 105:172099
ED Entered STN: 15 Nov 1986
GI



I



II

AB Total chiral synthesis of all relevant diastereoisomers established the structures of punaglandins 3 and 4 as I and II, resp., instead of the C-12(S) isomers, as proposed earlier.

IT 96055-66-2P 103384-67-4P 103531-36-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 96055-66-2 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 103384-67-4 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7E,12α,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 103531-36-8 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 96055-65-1P 96055-66-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of)
RN 96055-65-1 HCAPLUS
CN Prosta-7,10,14,17-tetraen-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-66-2 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 44 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:533647 HCAPLUS Full-text
DOCUMENT NUMBER: 105:133647
ORIGINAL REFERENCE NO.: 105:21561a,21564a

TITLE: Antitumor 4-hydroxy-2-cyclopentenones
INVENTOR(S): Hazato, Atsuo; Sugiura, Satoshi; Kurozumi, Seizi; Noyori, Ryoji
PATENT ASSIGNEE(S): Teijin Ltd. , Japan
SOURCE: Eur. Pat. Appl., 66 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 180399	A2	19860507	EP 1985-307631	19851022 <--
EP 180399	A3	19870616		
EP 180399	B1	19920520		
R: CH, DE, FR, GB, IT, LI, SE				
JP 61100542	A	19860519	JP 1984-220475	19841022 <--
JP 02020616	B	19900510		
JP 61100538	A	19860519	JP 1984-220476	19841022 <--
JP 61189245	A	19860822	JP 1985-28429	19850218 <--
JP 04019214	B	19920330		
JP 61291538	A	19861222	JP 1985-130845	19850618 <--
JP 06035422	B	19940511		

PRIORITY APPLN. INFO.:
JP 1984-220475 A 19841022 <--
JP 1984-220476 A 19841022 <--
JP 1985-28429 A 19850218 <--
JP 1985-130845 A 19850618 <--

OTHER SOURCE(S): CASREACT 105:133647; MARPAT 105:133647
ED Entered STN: 18 Oct 1986
GI



I

AB Cyclopentenones I [X = H, halo; A = H; B = OH, AB = bond; R1 = C1-10 (un)substituted alkyl, alkenyl, alkynyl; R2 = C1-10 (un)substituted alkyl, alkenyl, alkynyl; R3 = H, OH-protective group when R2 ≠ 2-octenyl, 8-acetoxy-2-octenyl, 2,5-octadienyl], useful as antitumor agents, are prepared Thus, (E)- and (Z)-2-chloro-4-hydroxy-5-(6- methoxycarbonylhexylidene)-4-octyl-2-cyclopentenone were prepared in 6 steps from 3-chloro-4-tert-butyldimethylsilyloxy-2-cyclopentenone and Me(CH2)7MgBr. The IC50 (inhibitory concentration) of 2-chloro-4-hydroxy-4-[3- (3,4-dimethoxyphenyl)propyl]-2-(6-methoxycarbonylhexylidene)-2- cyclopentenone was 0.06 μg/mL vs. L1210 leukemia cells in vitro.

IT 102355-12-4P 102355-13-5P 104248-43-3P 104248-48-8P 104248-51-3P 104248-75-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as antitumor agent)

RN 102355-12-4 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (7E,12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 102355-13-5 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (7Z,12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 104248-43-3 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 10-chloro-12-hydroxy-15,19-dimethyl-9-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 104248-48-8 HCAPLUS
CN 3-Cyclopentene-1-heptanoic acid, 3-chloro-5-[3-(3,4-dimethoxyphenyl)propyl]-ζ,5-dihydroxy-2-oxo-, methyl ester (CA INDEX NAME)



RN 104248-51-3 HCAPLUS
CN Heptanoic acid, 7-[4-chloro-2-[3-(3,4-dimethoxyphenyl)propyl]-2-hydroxy-5-oxo-3-cyclopenten-1-ylidene]-, methyl ester (CA INDEX NAME)



RN 104248-75-1 HCAPLUS
CN 2-Cyclopenten-1-one, 2-chloro-5-(3,7-dimethyl-2,6-octadien-1-ylidene)-4-hydroxy-4-(4-phenoxybutyl)- (CA INDEX NAME)



L43 ANSWER 45 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:406327 HCAPLUS Full-text
DOCUMENT NUMBER: 105:6327
ORIGINAL REFERENCE NO.: 105:1177a,1180a
TITLE: Synthesis of punaglandins and related compounds
AUTHOR(S): Suzuki, Masaaki; Morita, Yasushi; Yanagisawa, Akira; Noyori, Ryoji
CORPORATE SOURCE: Dep. Chem., Nagoya Univ., Japan
SOURCE: Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1985), 27th, 397-404
CODEN: TYKYDS
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese
ED Entered STN: 13 Jul 1986
AB Review with 12 refs.
IT 96055-63-9P 96055-64-0P 96055-65-1P
96055-66-2P 102355-12-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antitumor activity of)

RN 96055-63-9 HCAPLUS
CN Prosta-10,14,17-trien-1-oic acid, 5,6,7-tris(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7R,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-64-0 HCAPLUS
CN Prosta-10,14-dien-1-oic acid, 5,6,7-tris(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7R,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-65-1 HCAPLUS
CN Prosta-7,10,14,17-tetraen-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-66-2 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 102355-12-4 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (7E,12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L43 ANSWER 46 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:224750 HCAPLUS Full-text
DOCUMENT NUMBER: 104:224750
ORIGINAL REFERENCE NO.: 104:35643a,35646a
TITLE: Prostaglandin chemistry. XXVIII. Synthesis of new antineoplastic alkylidenecyclopentenones
AUTHOR(S): Sugiura, Satoshi; Hazato, Atsuo; Tanaka, Toshio; Okamura, Noriaki; Bannai, Kiyoshi; Manabe, Kenji; Kurozumi, Seizi; Suzuki, Masaaki; Noyori, Ryoji
CORPORATE SOURCE: Inst. Bio-Med. Res., Teijin Ltd., Hino, 191, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1985), 33(9), 4120-3
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 104:224750
ED Entered STN: 27 Jun 1986
GI



I

II III

AB The clavulone analog I, the punaglandin analog II, and their ω-chain-saturated analogs were prepared from, e.g., the cyclopentenones III (R = H, Cl). The compds. had potent growth-inhibiting activity against L1210 tumor cells.

IT 102355-12-4P 102355-13-5P 102419-55-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 102355-12-4 HCAPLUS

CN Prosta-7,10-dien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (7E,12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 102355-13-5 HCAPLUS

CN Prosta-7,10-dien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (7Z,12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 102419-55-6 HCAPLUS

CN Prosta-7,10,13-trien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (7E,12ξ,13E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L43 ANSWER 47 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:224749 HCAPLUS Full-text
DOCUMENT NUMBER: 104:224749
ORIGINAL REFERENCE NO.: 104:35643a,35646a
TITLE: Synthesis of a halogenated clavulone analog
AUTHOR(S): Nagaoka, Hiroto; Miyakoshi, Tohru; Kasuga, Junichi; Yamada, Yasuji
CORPORATE SOURCE: Tokyo Coll. Pharm., Hachioji, 192-03, Japan
SOURCE: Tetrahedron Letters (1985), 26(41), 5053-6
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 104:224749
ED Entered STN: 27 Jun 1986
GI



AB Chiral 10-chloroclavulone I was prepared via coupling of the key intermediates II and III. I had 10 times the growth inhibiting activity of clavulone II toward melanoma B16 cells.
IT 102354-92-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 102354-92-7 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7E,12α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 102354-91-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for punaglandin derivative)
RN 102354-91-6 HCAPLUS
CN Prosta-7,10-dien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, (5S,6R,7E,12α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 48 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:193175 HCAPLUS Full-text
DOCUMENT NUMBER: 104:193175
ORIGINAL REFERENCE NO.: 104:30483a,30486a
TITLE: Punaglandins and pharmaceutical use thereof
INVENTOR(S): Fukushima, Masanori; Kurozumi, Seizi; Scheuer, Paul J.; Yu, Patrick T. K.
PATENT ASSIGNEE(S): University of Hawaii, USA
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 8503706	A1	19850829	WO 1985-US226		19850214 <--
W: JP					
RW: CH, DE, FR, GB					
EP 172233	A1	19860226	EP 1985-901218		19850214 <--
R: CH, DE, FR, GB, LI					
JP 61501703	T	19860814	JP 1985-501005		19850214 <--
PRIORITY APPLN. INFO.:			US 1984-579933	A	19840214 <--
			WO 1985-US226	W	19850214 <--

OTHER SOURCE(S): MARPAT 104:193175
ED Entered STN: 01 Jun 1986
GI



I

AB Punaglandins I (R1 = H, Cl-10 alkyl, or cation; R2-R4 = H, C2-10 acyl) have antitumor activity. Punaglandin 3 (II) and punaglandin 4 (III) (R1 = Me; R2-3 = Ac; R4 = H; double bond for II, single bond for III) are extracted from the Telesto riisei. II and III showed IC50 values of 0.10 and 0.030 μg/mL against the proliferation of L 1210 carcinoma cells in culture.

IT 96055-65-1 96055-66-2
RL: PROC (Process)
(isolation of, from Telesto riisei, as neoplasm inhibitor)

RN 96055-65-1 HCAPLUS

CN Prosta-7,10,14,17-tetraen-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-66-2 HCAPLUS

CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 49 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:85634 HCAPLUS Full-text
DOCUMENT NUMBER: 104:85634
ORIGINAL REFERENCE NO.: 104:13541a,13544a
TITLE: Marine natural products. Part XII. Chlorovulones, new halogenated marine prostanoids with an antitumor activity from the stolonifer Clavularia viridis Quoy and Gaimard
AUTHOR(S): Iguchi, Kazuo; Kaneta, Soichiro; Mori, Kenichiro; Yamada, Yasuji; Honda, Atsushi; Mori, Yo
CORPORATE SOURCE: Tokyo Coll. Pharm., Hachioji, 192-03, Japan
SOURCE: Tetrahedron Letters (1985), 26(47), 5787-90
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 22 Mar 1986
GI



I



II



III

AB New halogenated marine prostanoids, chlorovulone I, II, and III (I-III, resp.) were isolated from the stolonifer C. viridis. The structure elucidation and the antitumor activity of chlorovulones were described.
IT 100201-69-2 100295-79-2 100295-80-5
100295-81-6
RL: BIOL (Biological study)
(of stolonifer, structure of)
RN 100201-69-2 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5Z,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 100295-79-2 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 100295-80-5 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5E,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 100295-81-6 HCAPLUS
CN Prosta-5,7,10,14-tetraen-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (5Z,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L43 ANSWER 50 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:615067 HCAPLUS Full-text
DOCUMENT NUMBER: 103:215067
ORIGINAL REFERENCE NO.: 103:34655a,34658a
TITLE: 4-Hydroxy-2-cyclopentenone derivatives
PATENT ASSIGNEE(S): Teijin Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60097926	A	19850531	JP 1983-205868	19831104 <--
JP 04063056	B	19921008		

PRIORITY APPLN. INFO.: JP 1983-205868 19831104 <--
ED Entered STN: 28 Dec 1985
GI



AB Title compds. I [R = H, halo; R1, R2 = H, OH; R1R2 = bond; R3 = H, (un)substituted alkyl, alkenyl, cycloalkyl; R4 = alkyl, cycloalkyl; R5 = H, OH, protected OH; Z = C.tplbond.C, CH:CH, CH2CH2], useful as anticancers and virucides (no data), were prepared Thus, stirring cyclopentenone II (R6 = H) with Me3COOH in benzene gave 10% II (R6 = OH).
IT 99210-09-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 99210-09-0 HCAPLUS
CN Prosta-7,10,13-trien-1-oic acid, 10-chloro-12-hydroxy-9-oxo-, methyl ester, (12ξ)- (9CI) (CA INDEX NAME)

Double bond geometry unknown.



L43 ANSWER 51 OF 51 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:218647 HCAPLUS Full-text
DOCUMENT NUMBER: 102:218647
ORIGINAL REFERENCE NO.: 102:34255a,34258a
TITLE: Punaglandins: halogenated antitumor eicosanoids from the octocoral Telesto riisei
AUTHOR(S): Baker, Bill J.; Okuda, Roy K.; Yu, Patrick T. K.; Scheuer, Paul J.
CORPORATE SOURCE: Dep. Chem., Univ. Hawaii Manoa, Honolulu, HI, 96822, USA
SOURCE: Journal of the American Chemical Society (1985), 107(10), 2976-7
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 29 Jun 1985
GI



I

AB T. riisei Collected in Hawaii contained 4 new eicosanoids, punaglandins 1-4, which bear Cl at C-10. Their structures, including relative stereochem., were determined by spectral and chemical methods. A Δ7 constituent, punaglandin 3 (I), inhibited L 1210 leukemia cell proliferation with an half-maximum ID value of 0.02 μg/mL.

IT 96055-65-1
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(of coral, antitumor activity and structure of)
RN 96055-65-1 HCAPLUS
CN Prosta-7,10,14,17-tetraen-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 96055-63-9 96055-64-0 96055-66-2
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(of coral, structure of)
RN 96055-63-9 HCAPLUS
CN Prosta-10,14,17-trien-1-oic acid, 5,6,7-tris(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7R,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-64-0 HCAPLUS
CN Prosta-10,14-dien-1-oic acid, 5,6,7-tris(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6R,7R,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-66-2 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7E,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 96055-67-3P 96055-68-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 96055-67-3 HCAPLUS
CN Prosta-7,10,14,17-tetraen-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,14Z,17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 96055-68-4 HCAPLUS
CN Prosta-7,10,14-trien-1-oic acid, 5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxo-, methyl ester, (5S,6S,7Z,14Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



Search History

```
L1            1 SEA ABB=ON  PLU=ON  US2005-521570/APPS
                D SCAN
                SEL RN

     FILE 'REGISTRY' ENTERED AT 10:09:43 ON 30 SEP 2008
L2           30 SEA ABB=ON  PLU=ON  (1029-96-5/BI OR 123941-77-5/BI OR
                133407-86-0/BI OR 13345-51-2/BI OR 140879-24-9/BI OR 142805-56-
                9/BI OR 143180-75-0/BI OR 155545-33-8/BI OR 155545-34-9/BI OR
                160791-07-1/BI OR 2353-33-5/BI OR 33069-62-4/BI OR 33419-42-0/B
                I OR 458-37-7/BI OR 538-58-9/BI OR 5956-04-7/BI OR 71503-81-6/B
                I OR 73211-11-7/BI OR 7689-03-4/BI OR 79655-73-5/BI OR
                83159-26-6/BI OR 83159-28-8/BI OR 86480-67-3/BI OR 87893-54-7/B
                I OR 89354-63-2/BI OR 9037-42-7/BI OR 96055-64-0/BI OR
                96055-65-1/BI OR 96055-66-2/BI OR 96055-68-4/BI)
L3            5 SEA ABB=ON  PLU=ON  L2 AND CL>=1 AND O>=6
                D SCAN
L4              STRUCTURE UPLOADED
                D
L5            0 SEA SSS SAM L4
L6            0 SEA SSS FUL L4
L7              STRUCTURE UPLOADED
                D
L8            0 SEA SSS SAM L7
L9              STRUCTURE UPLOADED
                D
L10           0 SEA SSS SAM L9
L11             STRUCTURE UPLOADED
                D
L12           0 SEA SSS SAM L11
L13             STRUCTURE UPLOADED
                D
L14           0 SEA SSS SAM L13
L15           0 SEA SSS FUL L11
L16             STRUCTURE UPLOADED
                D
L17           3 SEA SSS SAM L16
L18             STRUCTURE UPLOADED
                D
L19          12 SEA SSS SAM L18
                D SCAN
L20           0 SEA ABB=ON  PLU=ON  L19 AND L2
L21         242 SEA SSS FUL L18
L22           5 SEA ABB=ON  PLU=ON  L21 AND L2

     FILE 'HCAPLUS' ENTERED AT 10:58:08 ON 30 SEP 2008
L23         127 SEA ABB=ON  PLU=ON  L21
L24         107 SEA ABB=ON  PLU=ON  L23 AND (PRY<=2002 OR AY<=2002 OR PY<=2002)
L25         107 SEA ABB=ON  PLU=ON  L23 AND (PRY<=2002 OR AY<=2002 OR PY<=2002)

     FILE 'REGISTRY' ENTERED AT 11:45:32 ON 30 SEP 2008
L26             STRUCTURE UPLOADED
L27           8 SEA SUB=L21 SSS SAM L26
L28         173 SEA SUB=L21 SSS FUL L26
L29           5 SEA ABB=ON  PLU=ON  L28 AND L2
```

```
     FILE 'HCAPLUS' ENTERED AT 11:47:37 ON 30 SEP 2008
L30           75 SEA ABB=ON  PLU=ON  L28
L31            0 SEA ABB=ON  PLU=ON  L20 AND (PRY<=2002 OR AY<=2002 OR PY<=2002)
L32           63 SEA ABB=ON  PLU=ON  L30 AND (PRY<=2002 OR AY<=2002 OR PY<=2002)


     FILE 'REGISTRY' ENTERED AT 11:49:37 ON 30 SEP 2008
L33               STRUCTURE UPLOADED
L34            5 SEA SUB=L21 SSS SAM L33
L35          141 SEA SUB=L21 SSS FUL L33

     FILE 'HCAPLUS' ENTERED AT 11:52:15 ON 30 SEP 2008
L36           62 SEA ABB=ON  PLU=ON  L35
L37           52 SEA ABB=ON  PLU=ON  L36 AND (PRY<=2002 OR AY<=2002 OR PY<=2002)
L38           20 SEA ABB=ON  PLU=ON  MULLALLY J?/AU
L39            1 SEA ABB=ON  PLU=ON  L38 AND L37

     FILE 'REGISTRY' ENTERED AT 11:55:08 ON 30 SEP 2008
L40               STRUCTURE UPLOADED
L41            0 SEA SUB=L21 SSS SAM L40
L42            0 SEA SUB=L21 SSS FUL L40

     FILE 'HCAPLUS' ENTERED AT 11:58:33 ON 30 SEP 2008

L43           51 SEA ABB=ON  PLU=ON  L37 NOT L39
```